Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59067

Leo, C; Fink, D (2011). Erythropoietin in der onkologischen Therapie – was wissen wir über die Risiken? Praxis, 100(20):1239-46.

[img]Published Version
PDF - Registered users only
886Kb

Abstract

Erythropoietin is a glycoprotein predominantly produced in the kidney. It is an essential regulator of erythropoiesis in the bone marrow. Although cancer-associated anemia is caused by multiple factors, recombinant erythropoietin (rhuEpo) was widely used to treat and prevent this condition. Several clinical studies showed that the use of rhuEpo results in an efficient reduction of red blood cell transfusions in cancer-associated anemia. However, over the past twenty years, Epo and its receptor EpoR were found to be expressed also outside the hematopoietic system and in malignant tumors. This led to a discussion concerning potential risks associated with the application of erythropoiesis-stimulating agents in oncology.

Other titles:Erythropoietinin oncologic therapy - what so we know about the risks?
Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
DDC:610 Medicine & health
Language:German
Date:2011
Deposited On:17 Feb 2012 13:24
Last Modified:09 Oct 2013 13:11
Publisher:Hans Huber
ISSN:1661-8157 (P) 1661-8165 (E)
Publisher DOI:10.1024/1661-8157/a000689
PubMed ID:21971618
Citations:Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page